LS Investment Advisors LLC held its position in shares of Chemed Corp. (NYSE:CHE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 635 shares of the company’s stock at the end of the second quarter. LS Investment Advisors LLC’s holdings in Chemed Corp. were worth $130,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Teachers Advisors LLC raised its position in shares of Chemed Corp. by 2.6% in the fourth quarter. Teachers Advisors LLC now owns 29,537 shares of the company’s stock worth $4,738,000 after buying an additional 744 shares in the last quarter. Private Trust Co. NA acquired a new position in shares of Chemed Corp. during the first quarter worth $455,000. Parametrica Management Ltd acquired a new position in shares of Chemed Corp. during the first quarter worth $352,000. Louisiana State Employees Retirement System raised its position in shares of Chemed Corp. by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the company’s stock worth $1,206,000 after buying an additional 100 shares in the last quarter. Finally, Boston Advisors LLC acquired a new position in shares of Chemed Corp. during the first quarter worth $1,906,000. Institutional investors and hedge funds own 98.33% of the company’s stock.
Shares of Chemed Corp. (CHE) traded down 0.008% during trading on Friday, reaching $192.165. The company’s stock had a trading volume of 44,170 shares. The company has a 50 day moving average of $201.85 and a 200 day moving average of $191.74. The company has a market cap of $3.07 billion, a PE ratio of 47.672 and a beta of 1.14. Chemed Corp. has a 12-month low of $130.05 and a 12-month high of $216.01.
Chemed Corp. (NYSE:CHE) last issued its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm had revenue of $415.06 million for the quarter, compared to analysts’ expectations of $407.56 million. During the same period in the previous year, the firm posted $1.80 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. On average, analysts anticipate that Chemed Corp. will post $8.20 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Monday, August 14th will be paid a dividend of $0.28 per share. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a yield of 0.58%. The ex-dividend date is Thursday, August 10th. Chemed Corp.’s payout ratio is presently 26.07%.
A number of equities analysts have weighed in on CHE shares. Zacks Investment Research lowered Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. BidaskClub lowered Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 22nd. Royal Bank Of Canada restated a “hold” rating and issued a $208.00 target price on shares of Chemed Corp. in a research note on Wednesday, July 5th. TheStreet lowered Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Finally, Oppenheimer Holdings, Inc. upped their target price on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $218.33.
In other Chemed Corp. news, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $201.16, for a total transaction of $3,017,400.00. Following the completion of the transaction, the insider now owns 173,801 shares in the company, valued at $34,961,809.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George J. Walsh III bought 1,000 shares of the company’s stock in a transaction on Monday, June 26th. The shares were acquired at an average price of $204.56 per share, with a total value of $204,560.00. Following the transaction, the director now directly owns 7,908 shares of the company’s stock, valued at $1,617,660.48. The disclosure for this purchase can be found here. Insiders own 5.32% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.